Nano CBD. Liposomal CBD. Advanced technology. Faster absorption. Higher bioavailability.
If you search online for CBD capsules or CBD gummies, you’ll come across these terms more and more often. The promise is clear: better absorption means you need less, which ultimately makes it more cost-effective.
But is that really true? Or are you mainly paying for smart marketing?
In this blog, we explain what nano and liposomal CBD actually are, the theory behind them, and why these forms are not the most logical choice for many people.
What is meant by nano CBD and liposomal CBD?
Nano CBD refers to CBD that has been reduced to extremely small particles. Through this so-called “nano-emulsion,” the body is supposed to absorb the compound faster and more efficiently.
Liposomal CBD uses fat-like spheres — liposomes — that are designed to protect the CBD molecule and transport it more effectively through the body.
In theory, this sounds interesting. CBD is fat-soluble, meaning it does not naturally dissolve easily in water. By modifying its structure, absorption could potentially improve.
However, theory and practice are two different things.
The claim of higher bioavailability
Many producers of nano or liposomal CBD claim significantly increased bioavailability. This means that a larger percentage of the CBD you consume supposedly reaches your bloodstream.
Research does show that the method of administration influences absorption (1). For example, sublingual use via CBD oil may result in different absorption compared to oral intake through capsules.
But:
The differences between standard oil, capsules, gummies, and advanced nano-formulas are less spectacular in independent studies than marketing often suggests (2).
Moreover, many factors play a role beyond particle size alone:
-
your metabolism
-
body fat percentage
-
what you have eaten
-
liver activity
-
individual sensitivity of your endocannabinoid system
A “3x better absorption” on paper does not automatically mean you will experience 3x more effect.
Capsules and gummies: what are you really paying for?
When nano or liposomal CBD is processed into CBD capsules or CBD gummies, absorption still takes place through the digestive system.
This means the CBD must first pass through the stomach and liver before entering the bloodstream. This process — known as first-pass metabolism — remains the same, whether the product is nano-based or not (3).
In other words, the “technological upgrade” does not fundamentally change the absorption pathway.
What often does change is the price.
Nano and liposomal products are typically significantly more expensive per milligram of CBD. You are paying for:
-
additional production steps
-
patented techniques
-
marketing claims
-
premium positioning
Not necessarily for demonstrably better results.
The role of marketing in the CBD industry
The CBD market is highly competitive. Producers constantly look for ways to stand out. Terms like nano, liposomal, and water-soluble sound innovative and scientific.
That does not automatically mean they are bad. But it also does not mean they are necessarily better.
In fact, some studies suggest that consuming traditional CBD oil with a high-fat meal can significantly increase absorption (4). That is a simple, natural way to influence bioavailability — without paying extra for complex technology.
What makes the most sense for most people?
For a broad audience, the following usually makes the most sense:
-
A high-quality full spectrum extract
-
Transparent laboratory analyses
-
Consistent dosing
-
A format that fits your lifestyle
Capsules and gummies are mainly convenient. They are discreet, easy to carry, and simple to dose. But do not expect miracles from “nano” if the product still follows the same digestive process.
If you want maximum control over dosing and absorption, many people choose sublingual use via oil. In this case, part of the CBD is absorbed directly through the oral mucosa.
Ultimately, it is less about hype and more about quality, consistency, and personal experience.
As is often the case with natural support: simplicity usually beats complexity.
“The power of a product is not in the label, but in what it actually does for your body.”
Sources
-
Millar SA et al. (2018). A systematic review on the pharmacokinetics of cannabidiol in humans. Frontiers in Pharmacology.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275223/ -
Zgair A et al. (2016). Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. American Journal of Translational Research.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009397/ -
Huestis MA. (2007). Human cannabinoid pharmacokinetics. Chemistry & Biodiversity.
https://pubmed.ncbi.nlm.nih.gov/17712819/ -
Birnbaum AK et al. (2019). Food effect on pharmacokinetics of cannabidiol oral capsules. Epilepsia.
https://pubmed.ncbi.nlm.nih.gov/30347298/
